The price of Synaptogenix Inc (NASDAQ:SNPX) shares last traded on Wall Street rose 5.67% to $0.38.
Based on available information, 1 analysts follow Synaptogenix Inc (NASDAQ:SNPX). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $14.00 and a low of $14.00, we find $14.00. Given the previous closing price of $0.36, this indicates a potential upside of 3788.89 percent. SNPX stock price is now -33.02% away from the 50-day moving average and -62.67% away from the 200-day moving average. The market capitalization of the company currently stands at $3.86M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Among analysts, 1 rate the stock a hold while 0 rate it a buy. Brokers who have rated the stock have averaged $14.00 as their price target over the next twelve months.
In other news, TUCHMAN ALAN J, Chief Executive Officer sold 27,000 shares of the company’s stock on Dec 16. The stock was sold for $31,641 at an average price of $1.17. Upon completion of the transaction, the Chief Executive Officer now directly owns 33,000 shares in the company, valued at $12540.0. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 16, Chief Financial Officer WEINSTEIN ROBERT sold 27,000 shares of the business’s stock. A total of $31,641 was realized by selling the stock at an average price of $1.17. This leaves the insider owning 33,198 shares of the company worth $12615.24. Insiders disposed of 115,762 shares of company stock worth roughly $43989.56 over the past 1 year. A total of 4.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SNPX stock. A new stake in Synaptogenix Inc shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $6,000. FIDUCIARY ALLIANCE LLC invested $1,000 in shares of SNPX during the first quarter. In total, there are 24 active investors with 3.51% ownership of the company’s stock.
During the past 12 months, Synaptogenix Inc has had a low of $0.26 and a high of $7.73. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 12.05, and a quick ratio of 12.05. The fifty day moving average price for SNPX is $0.5563 and a two-hundred day moving average price translates $0.9951 for the stock.
The latest earnings results from Synaptogenix Inc (NASDAQ: SNPX) was released for Jun, 2023.
Synaptogenix Inc(SNPX) Company Profile
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.
